2022-2027 US Tobacco Market Report and Forecast

Jan.09.2023
2022-2027 US Tobacco Market Report and Forecast
Research report shows the US tobacco market value to reach $88.12 billion in 2022, with cigarettes and e-cigarettes dominating.

On January 6th, renowned market research firm, Research and Markets, released their 2022-2027 market report and forecast for the United States. The report revealed that the tobacco market in the US is expected to reach a size of $88.12 billion in 2022. In contrast, according to data published by Hunan Beizheshi Information Consulting Co. Ltd., China's cigarette market is projected to reach RMB 491.256 billion ($71.83 billion) that same year.


Source: Research and Markets.


Market Segmentation: By Product: According to this report, the market is divided into five segments based on product: cigarettes, e-cigarette products, moist snuff tobacco (MST), cigars and cigarillos, and nicotine pouches. By 2021, cigarettes hold the largest share of the market in both value and quantity, followed by e-cigarette products. As people become increasingly aware that e-cigarette products are safer than traditional cigarettes, particularly among young people, the future of the e-cigarette market looks promising. On the other hand, due to growing interest in alternative products, the nicotine pouch market is expected to grow significantly in the coming years with a compound annual growth rate. By Distribution Channel: According to this report, the market is divided into two segments based on distribution channel: offline and online. In 2021, the offline segment holds the majority share of the market. Small and large companies sell their products through offline retail channels due to the presence of large consumer groups such as grocery stores. Online channels are expected to achieve the highest compound annual growth rates in the predicted years due to increased advertising and promotion expenses by major players operating in the market, thereby bringing significant growth to this segment in the coming years.


Market trends: Growth drivers: One of the most important factors impacting the nicotine market in the United States is the increase in the number of smokers and the growth of the workforce. As lifestyles become centered around work and offices, the stress and anxiety levels of workers are increasing, causing an increase in the consumption of stress-relieving agents such as nicotine. Additionally, factors such as personal income increases, the popularity of e-cigarettes, a shift towards next-generation products, peer influence among young people, and increased investment in research and development have led to the market's growth over the past few years. Challenges: However, the market has been facing specific challenges such as strict regulations, increased taxation on tobacco products, and the harmful effects of nicotine. Trends: Due to various new trends such as the increasing influence of social media, the growing influence of parties and popular culture, the strong penetration of organized retail networks, and the popularity of smoke-free alternatives, the market is expected to rapidly grow for nicotine products such as oral nicotine during the forecast period. Party and bar culture is increasingly popular among the millennial and working-class communities, especially stimulating demand for flavored and unflavored cigarettes. Additionally, social media is being used more and more to increase awareness of the health benefits of transitioning from combustible smoking to e-cigarettes and vapor products. This has heightened personal accessibility to different brands, thereby increasing demand for non-combustible nicotine products.


Competition Landscape:


Due to a relatively small number of market players, the nicotine market in the United States is concentrated. Altria is the market leader in tobacco products and dominates the entire nicotine industry.


The main participants in the American nicotine market are:


British American Tobacco P.L.C. (BAT), Turning Point Brands Inc., Altria Group Inc. (Altria), Scandinavian Tobacco Group, Imperial Brands PLC, Philip Morris International Inc. (PMI), Swedish Match AB, JUUL Labs, Inc., Swisher, and Vector Group Ltd. are all major players in the tobacco industry.


Altria is the leading company in the United States market for tobacco and moist snuff products. However, its share is expected to decrease in the coming years due to the unfavorable shift towards niche markets, such as e-cigarettes, that are below Altria's index, as well as some losses in the tobacco and moist snuff markets. The share and market leadership of e-cigarettes have been rapidly changing, with JUUL's leadership since 2019 being replaced by BAT's VUSE. Meanwhile, although JUUL's share in the US e-cigarette market is expected to decline, its market value share is predicted to increase by 2025.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana's Alcohol and Tobacco Commission (ATC) ordered tobacco certificate holders in September to remove certain vaping products marketed under Elf Bar, Lost Mary, MR FOG, iJOY and other brands from inventory under the state's foreign-adversary product law. The agency later listed 257 MR FOG products and 77 Lost Mary product entries as lawful for sale. The Lost Mary revision expressly stated that compliance evidence had been received for 20 additional products. 2Firsts compliance expert Kurt said potential filings could include e-liquid and ingredient-origin records, U.S. nicotine-analog supply-chain documentation and FDA premarket application status.
Regulations
Oct.08
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
The House-passed FY2027 National Defense Authorization Act includes a provision authorizing the defense secretary to conduct a one-year smoking-cessation pilot for active-duty service members. Section 707 lists counseling, nicotine gum and patches alongside what the bill calls "electric nicotine delivery systems," nicotine pouches and heat-not-burn products. A recent Washington Examiner op-ed cited ZYN as an example in arguing for the provision, but the legislation does not name any commercial brand or supplier. ZYN is made by PMI-owned Swedish Match USA, with specified products holding FDA marketing authorizations and modified risk orders.
Sep.20
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia will place e-cigarettes and related nicotine products under its “strategic goods” framework from August 20, 2026. According to TVP World’s report published on August 19, the newly listed items include e-cigarettes, electronic smoking devices, vape liquids and nicotine salts. Individuals who illegally move these products across Russia’s customs border or its state border with other Eurasian Economic Union (EAEU) members could face up to five years in prison if shipment values exceed 100,000 rubles (about €1,000), provided all elements of a criminal offence are established.
Aug.20
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
South Korea Constitutional Court Upholds Volume-Based E-Liquid Tax, With Challenged Rates at KRW 370 and KRW 628 per Milliliter
South Korea Constitutional Court Upholds Volume-Based E-Liquid Tax, With Challenged Rates at KRW 370 and KRW 628 per Milliliter
South Korea's Constitutional Court has upheld fixed taxes on nicotine-containing e-cigarette liquids based on solution volume, ruling that challenged provisions imposing KRW 370 per milliliter in individual consumption tax and KRW 628 per milliliter in tobacco consumption tax do not violate the Constitution. The cases stemmed from historical disputes involving importers that reported nicotine as being extracted from tobacco stems rather than leaves. South Korea has since broadened its tobacco definition to include synthetic nicotine, while current tax laws provide reduced rates for certain products not derived from tobacco.
Sep.18